Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: A retrospective review of FDA adverse events reporting system (FAERS)

被引：0
|
作者：
Sahu, Y. [1 ]
Ensor, J. [2 ]
Burns, E. [3 ]
Sahu, G. [4 ]
Iyer, S. P. [5 ]
Anand, K. [6 ]
机构：
[1] Safdarjang Hosp, Opthalmol, New Delhi, India
[2] Houston Methodist Res Inst, Oncol, Houston, TX USA
[3] Houston Methodist Hosp, Canc Ctr, Houston, TX 77030 USA
[4] Creighton Univ, Sch Med, Psychiat, North Platte, NE USA
[5] Univ Texas MD Anderson Canc Ctr, Lymphoma Myeloma, Houston, TX 77030 USA
[6] Great Plains Hlth, Canc Ctr, North Platte, NE USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43P
引用
收藏
页码：S1433 / S1433
页数：1
相关论文
共 50 条
  • [31] Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
    Griewing, Luisa Maria
    Schweizer, Claudia
    Schubert, Philipp
    Rutzner, Sandra
    Eckstein, Markus
    Frey, Benjamin
    Haderlein, Marlen
    Weissmann, Thomas
    Semrau, Sabine
    Gostian, Antoniu-Oreste
    Mueller, Sarina K.
    Traxdorf, Maximilian
    Iro, Heinrich
    Zhou, Jian-Guo
    Gaipl, Udo S.
    Fietkau, Rainer
    Hecht, Markus
    BMC CANCER, 2021, 21 (01)
  • [32] Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study
    Nigro, Olga
    Pinotti, Graziella
    Giusti, Raffaele
    Filetti, Marco
    De Galitiis, Federica
    Di Pietro, Francesca Romana
    Bersanelli, Melissa
    Lazzarin, Alessandro
    Catino, Annamaria
    Pizzutillo, Pamela
    Russano, Marco
    Torniai, Mariangela
    Ricciuti, Biagio
    Russo, Alessandro
    Tudini, Marianna
    Bolzacchini, Elena
    Di Marino, Pietro
    Rijavec, Erika
    Vallini, Ilaria
    Ficorella, Corrado
    Cortellini, Alessio
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [33] Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
    Luisa Maria Griewing
    Claudia Schweizer
    Philipp Schubert
    Sandra Rutzner
    Markus Eckstein
    Benjamin Frey
    Marlen Haderlein
    Thomas Weissmann
    Sabine Semrau
    Antoniu-Oreste Gostian
    Sarina K. Müller
    Maximilian Traxdorf
    Heinrich Iro
    Jian-Guo Zhou
    Udo S. Gaipl
    Rainer Fietkau
    Markus Hecht
    BMC Cancer, 21
  • [34] Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
    Nigro, O.
    Cortellini, A.
    Giusti, R.
    Marchetti, P.
    De Galitiis, F.
    Di Pietro, F. R.
    Bersanelli, M.
    Lazzarin, A.
    Galetta, D.
    Pizzutillo, P.
    Santini, D.
    Torniai, M.
    De Giglio, A.
    Russo, A.
    Silva, R. R.
    Bolzacchini, E.
    Natoli, C.
    Rijavec, E.
    Vallini, I.
    Pinotti, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Defining adverse events of anti -programmed-death-1 (Anti-PD1) agents using FDA adverse event reporting system (FAERS).
    Xiao, Kun
    Lian, Zhesi
    Collins, Robert
    Dimou, Anastasios
    Garrett-Mayer, Elizabeth
    Drabkin, Harry A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Osimertinib-Induced Cardiotoxicity A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
    Anand, Kartik
    Ensor, Joe
    Trachtenberg, Barry
    Bernicker, Eric H.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 172 - 178
  • [37] Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review
    Han, Deting
    Dong, Jianyong
    Li, Honglin
    Ma, Tao
    Yu, Wenjun
    Song, Lucheng
    MEDICINE, 2020, 99 (05) : E18701
  • [38] Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
    Zhang, You-Cheng
    Zhu, Tian-Chen
    Nie, Run-Cong
    Lu, Liang-He
    Xiang, Zhi-Cheng
    Xie, Dan
    Luo, Rong-Zhen
    Cai, Mu-Yan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [39] Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
    Chen, Juan
    Liu, Jia-Si
    Liu, Jun-Yan
    She, Lei
    Zou, Ting
    Yang, Fan
    Li, Xiang-Ping
    Wang, Zhan
    Liu, Zhaoqian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 10
  • [40] Ocular adverse events in PD1 and PDL1 inhibitors
    Young, LeAnne
    Sharon, Elad
    Streicher, Howard
    Chen, Helen
    Finnigan, Shanda
    Murray, James
    Sen, H. Nida
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
12345